On The Pen Launches Redesigned GLP-1 News Website As Independent Media Platform Expands
CEDAR FALLS, Iowa - September 15, 2026 - On The Pen, an independent GLP-1 news and media platform covering obesity medicine, diabetes, metabolic health and the pharmaceutical industry, has launched a redesigned version of OnThePen.
The refresh gives On The Pen a cleaner, more traditional digital newsroom with improved navigation, stronger breaking-news presentation and easier access to written reporting, podcasts, livestreams and video coverage.
The redesigned site expands On The Pen's role as a destination for top-ranked GLP-1 news, including coverage of Ozempic, Wegovy, Mounjaro, Zepbound, retatrutide, clinical trials, drug pricing, access, insurance, telehealth, compounding and pharmaceutical industry developments.
“On The Pen started because there was a deficit of information that actually spoke to them,” said founder Dave Knapp.“The new site gives that reporting a stronger home and makes it easier for people to understand what is happening in GLP-1 medicine and what it could mean for them.”
The website also gives greater prominence to On The Pen: The Weekly Dose Podcast, a top-ranked, award-winning GLP-1 podcast in the top 0.5% of all podcasts globally.
Together, the website, podcast and live programming position On The Pen as an independent multimedia source for GLP-1 news, obesity medicine coverage and patient-centered reporting.
About On The Pen
On The Pen is an independent GLP-1 news and media platform covering GLP-1 medications, obesity medicine, diabetes, metabolic health and the pharmaceutical industry. The platform publishes breaking GLP-1 news, original reporting, analysis, livestreams and On The Pen: The Weekly Dose Podcast. Its mission is to empower patients to have better conversations with their doctors.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment